Melphalan, @entity1487 , and @entity11796 in metastatic or recurrent XXXX . Preliminary report.

@entity1 @entity1204 @entity137 @entity11796 @entity1420 @entity882 @entity2268 @entity3601 @entity1962 @entity420 @entity1487
The purpose of this study was to evaluate therapy with @entity3601 , @entity1487 ( @entity1487 ), and @entity11796 combination (MFP) in @entity1 with metastatic or recurrent @entity1204 not amenable to surgery or radiation therapy, as compared to @entity1420 therapy alone. Previously, the authors have treated 114 @entity1 with @entity1420 therapy and achieved a 15.8% objective response rate; 7.0% were complete responders. Thirteen @entity1 with documented recurrent or metastatic @entity1204 were entered into the MFP study. Thirteen were evaluable for @entity137 and 11 for response (2 had no measureable parameter). Treatment consisted of melphalan 0.2 mg/kg/day for 4 days every 4 weeks; @entity1487 15 mg/kg/day for 4 days every 4 weeks; and @entity11796 1.0 g intramuscularly weekly. Two of the first 3 @entity1 who were treated with this regimen developed severe @entity882 (platelets, 25,000 and 17,000/mm3). Therefore, the remaining 10 @entity1 received @entity1487 at a dose of 10 mg/kg/day for 4 days every 4 weeks. Except for 1 @entity1 who devloped @entity2268 , there was no other significant @entity137 in the 90 courses of therapy received by the 13 @entity1 . Of the 11 @entity1 evaluable for respone, 6 (54.5%) responded (2 complete responders, 4 partial responders), 2 for stationary disease, and 3 progressed after having had stationary disease for 3, 6, and 9 months, respectively. Of special interest was that the 2 @entity1 with @entity1962 responded and 1 additional @entity1 with @entity420 maintained a complete response with @entity1487 therapy alone.
